Comparative Pharmacology
Head-to-head clinical analysis: KONAKION versus SYNKAYVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KONAKION versus SYNKAYVITE.
KONAKION vs SYNKAYVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phytonadione (vitamin K1) is a fat-soluble vitamin that serves as a cofactor for the hepatic microsomal enzyme vitamin K epoxide reductase, which is responsible for the post-translational carboxylation of glutamic acid residues (Gla residues) on clotting factors II, VII, IX, and X, as well as proteins C and S. Carboxylation allows these factors to bind calcium and phospholipids, enabling their activation in the coagulation cascade.
Menadiol sodium diphosphate is a water-soluble form of vitamin K (menadione) that serves as a cofactor for the gamma-carboxylation of glutamic acid residues in clotting factors II, VII, IX, X, and proteins C and S in the liver, enabling their calcium-dependent binding to phospholipid membranes and activation of the coagulation cascade.
1-10 mg IM or subcutaneously (slow IV infusion over 15-30 min if necessary) once; for warfarin reversal, dose based on INR: 1-2.5 mg PO if INR >5, 2.5-5 mg if INR >9, or 10 mg IV if major bleeding.
5 to 15 mg subcutaneously or intramuscularly once daily for 3 to 5 days; for anticoagulant reversal, 1 to 10 mg intravenously at 10 mg/min rate.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours for phytonadione; clinical effect on INR persists for 24-48 hours.
Terminal elimination half-life is approximately 2.5 hours (range 2-4 hours) in healthy adults; prolonged in patients with hepatic dysfunction.
Primarily fecal via bile (60-70%) and renal (10-20%) as metabolites; unchanged drug excretion is minimal.
Primarily fecal via bile (approximately 60-70% as metabolites, with little unchanged drug); renal excretion accounts for <5%.
Category C
Category C
Vitamin K
Vitamin K